ArticleCancer cell2014
CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance.
Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03792724 (Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Aptamer-Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer.Cancer immunology, immunotherapy : CII · 2025Article
- A Tc1- and Th1-T-lymphocyte-rich tumor microenvironment is a hallmark of MSI colorectal cancer.The Journal of pathology · 2025Article
- Tumor immunity: A brief overview of tumor‑infiltrating immune cells and research advances into tumor‑infiltrating lymphocytes in gynecological malignancies (Review).Experimental and therapeutic medicine · 2024Review
- Hypothesis of a CD137/Eomes activating axis for effector T cells in HPV oropharyngeal cancers.Molecular medicine (Cambridge, Mass.) · 2024Article
- Conventional type 1 dendritic cells (cDC1) in cancer immunity.Biology direct · 2023Review
- TIM-3 increases the abundance of type-2 dendritic cells during Leishmania donovani infection by enhancing IL-10 production via STAT3.Cell death & disease · 2023Article
- mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy.Cell reports. Medicine · 2023Article
- Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.Cancers · 2022Review
- Dendritic cell biology and its role in tumor immunotherapy.Journal of hematology & oncology · 2020Review
- CSF1R methylation is a key regulatory mechanism of tumor-associated macrophages in hepatocellular carcinoma.Oncology letters · 2020Article
- Trial watch: TLR3 agonists in cancer therapy.Oncoimmunology · 2020Review
- Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.Nature communications · 2019Article
- CD96 Is an Immune Checkpoint That Regulates CD8Cancer immunology research · 2019Article
- Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response.Scientific reports · 2017Article
- A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.Molecular therapy oncolytics · 2017Article
- Immunoplasticity in cutaneous melanoma: beyond pure morphology.Virchows Archiv : an international journal of pathology · 2017Review
- Deletion of Batf3-dependent antigen-presenting cells does not affect atherosclerotic lesion formation in mice.PloS one · 2017Article
- Advances in immunotherapy for the treatment of glioblastoma.Journal of neuro-oncology · 2017Review
- Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.Oncoimmunology · 2016Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mechanisms through which tumor antigen-specific T cells are elicited in natural or chemotherapy-induced immunosurveillance have been elusive. In this issue of Cancer Cell, two papers by Broz and colleagues and Ruffell and colleagues delineate an important role for a specific dendritic cell subset characterized by CD103 expression, dependence on transcription factors Batf3 and Irf8, and interleukin-12 production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.